Okamura et al. [14] reported longer progression free survival (PFS) after immune checkpoint inhibitors (ICIs) in ARID1A-mutated cancers [compared to wild-type (WT) tumors], and this result was independent of microsatellite instability or mutational burden. Here, ARID1A is linked to cancer.